Ptc Therapeutics (PTCT) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Ptc Therapeutics (PTCT) over the last 13 years, with Q4 2024 value amounting to $33.4 million.
- Ptc Therapeutics' Accumulated Depreciation & Amortization fell 3494.17% to $33.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $33.4 million, marking a year-over-year decrease of 3494.17%. This contributed to the annual value of $33.4 million for FY2024, which is 3494.17% down from last year.
- Per Ptc Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $33.4 million for Q4 2024, which was down 3494.17% from $51.3 million recorded in Q4 2023.
- In the past 5 years, Ptc Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $51.3 million in Q4 2023 and a low of $18.1 million during Q4 2020
- In the last 5 years, Ptc Therapeutics' Accumulated Depreciation & Amortization had a median value of $33.4 million in 2024 and averaged $33.4 million.
- As far as peak fluctuations go, Ptc Therapeutics' Accumulated Depreciation & Amortization crashed by 4387.2% in 2020, and later soared by 5044.29% in 2021.
- Ptc Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $18.1 million in 2020, then skyrocketed by 50.44% to $27.2 million in 2021, then soared by 37.52% to $37.4 million in 2022, then soared by 37.21% to $51.3 million in 2023, then crashed by 34.94% to $33.4 million in 2024.
- Its last three reported values are $33.4 million in Q4 2024, $51.3 million for Q4 2023, and $37.4 million during Q4 2022.